Last reviewed · How we verify
Higher dose icotinib
At a glance
| Generic name | Higher dose icotinib |
|---|---|
| Also known as | Commana |
| Sponsor | Betta Pharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases (PHASE2)
- IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer (NA)
- High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (PHASE4)
- Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy (PHASE2)
- Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR (PHASE2)
- High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC (PHASE2)
- High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease (PHASE2)
- Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Higher dose icotinib CI brief — competitive landscape report
- Higher dose icotinib updates RSS · CI watch RSS
- Betta Pharmaceuticals Co., Ltd. portfolio CI